Inhibrx’s Ozekibart Breaks New Ground in Chondrosarcoma, Driving Stock Surge

Inhibrx Biosciences’ targeted therapy ozekibart (formerly INBRX-109) achieved a major breakthrough in the Phase II ChonDRAgon trial, reducing the risk of disease progression or death by 52% versus placebo. Patients receiving ozekibart recorded a median progression-free survival of 5.52 months, more than double that of placebo. The treatment showed consistent efficacy across chondrosarcoma subgroups, including IDH-mutant cases. Following the results, Inhibrx’s shares jumped 61%, reflecting strong investor confidence. Although one liver toxicity–related death occurred before safety adjustments, subsequent hepatotoxicity incidents were mild. Inhibrx plans to file for FDA approval by mid-2026, which could make ozekibart the first targeted therapy for chondrosarcoma. Beyond this rare cancer, the drug has shown promising early results in colorectal and Ewing sarcoma, highlighting its broader oncology potential.

28-10-2025